{"entity":{"id":"her2-pet","kind":"technology","name":"HER2 PET","aka":[],"tldr":"HER2 PET is a PET scan using radiolabelled trastuzumab or smaller HER2 binders to map HER2 across all metastases at once.","summary":"HER2 PET images HER2 across every metastasis at once using a radiolabelled HER2 binder, either 89Zr-trastuzumab or smaller 68Ga- and 18F-labelled affibodies and nanobodies such as 68Ga-ABY-025 and 18F-GE-226. The result is a whole-body receptor map rather than a single biopsy, which matters because HER2 expression varies between lesions. The ZEPHIR and IMPACT trials studied these tracers, and uptake was predictive of response to T-DM1. It is most useful in heterogeneous HER2-low disease, where one biopsy may be unrepresentative and HER2-directed ADCs now have indications. Studied since 2010, it is not yet approved; trials have been small, and full-antibody tracers need days between injection and imaging, which smaller binders aim to shorten. It shows how much HER2 each tumour deposit carries without a needle.","status":"phase-2","asOf":"2026-09-04","links":[{"label":"Gebhart et al., ZEPHIR: molecular imaging of heterogeneity in advanced HER2-positive breast cancer with 89Zr-trastuzumab PET (Annals of Oncology 2016)","url":"https://doi.org/10.1093/annonc/mdv577"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","gastric"],"sections":["imaging","adcs"],"technologies":["pet","immuno-pet"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07527806","nct06369831","nct05619016"],"people":[],"bottlenecks":[],"keyPapers":["paper-gebhart-ann-oncol"],"journals":[],"dependsOn":[],"notes":[],"principle":"Radiolabelled HER2 binder; whole-body receptor map.","strengths":["Captures inter-lesion heterogeneity","Non-invasive re-assessment"],"limitations":["Not approved; small trials","Antibody tracers need days"],"since":2010},"route":"/technologies/her2-pet/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"trial":[{"id":"nct05619016","kind":"trial","name":"[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors","route":"/trials/nct05619016/"},{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/"},{"id":"nct07527806","kind":"trial","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","route":"/trials/nct07527806/"}],"paper":[{"id":"paper-gebhart-ann-oncol","kind":"paper","name":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","route":"/key-papers/paper-gebhart-ann-oncol/"}],"roadmap":[{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/"},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/"}],"person":[{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"}]}}